Radiology, Vol 179, 395-397, Copyright © 1991 by Radiological Society of North America
Renal tolerance for ioxaglate in patients with chronic renal failure [published erratum appears in Radiology 1991 Jul;180(1):291]
G Deray, P Cacoub, C Jacquiaud, G Drobinski, G Brillet, D Bunker, MC Jaudon, C Jacobs and G] Drobinski M$[corrected to Drobinski
Department of Nephrology, Hopital Pitie-Salpetriere, Paris, France.
The authors sought to evaluate renal tolerance for ioxaglate sodium
meglumine used as a contrast agent in patients with chronic renal failure.
Eight male patients (mean age, 55 years +/- 5) with chronic renal
insufficiency (glomerular filtration rate less than 60 mL/min) who
underwent diagnostic cardiac catheterization were enrolled. Renal clearance
of inulin and rho-aminohippuric acid and urinary enzyme excretion were
studied 1 day before and 1 day after administration of 167 mL +/- 43 of
ioxaglate. None of the patients experienced any adverse reactions. All the
patients had markedly depressed renal clearance values before angiography.
Mean serum creatinine level, glomerular filtration rate, effective renal
plasma flow, and urinary beta 2-microglobulin excretion were unaltered by
angiography. After the procedure, only one patient had an increase in serum
creatinine level of more than 10% (from 115 to 159 mumol/L [1.3 to 1.8
mg/dL]), with a decrease in glomerular filtration rate from 34 to 27
mL/min. In this patient, serum creatinine level and glomerular filtration
rate normalized within 72 hours. Using accurate and sensitive renal
function tests, the authors have shown that ioxaglate may be used safely in
patients with chronic renal failure.
